Daré Bioscience (DARE) Stock Forecast, Price & News

Daré Bioscience (NASDAQ:DARE) Frequently Asked Questions

Is Daré Bioscience a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Daré Bioscience stock.
View analyst ratings for Daré Bioscience or view top-rated stocks.

When is Daré Bioscience's next earnings date?

Daré Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Daré Bioscience.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) issued its quarterly earnings data on Thursday, March, 31st. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.03. During the same period in the previous year, the company earned ($0.22) earnings per share.
View Daré Bioscience's earnings history.

What price target have analysts set for DARE?

4 Wall Street analysts have issued 12-month price targets for Daré Bioscience's stock. Their forecasts range from $4.00 to $17.00. On average, they anticipate Daré Bioscience's stock price to reach $9.00 in the next year. This suggests a possible upside of 675.9% from the stock's current price.
View analysts' price targets for Daré Bioscience or view top-rated stocks among Wall Street analysts.

Who are Daré Bioscience's key executives?

Daré Bioscience's management team includes the following people:

• Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 55, Pay $563.74k)
• Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 63, Pay $400.32k)
• Mr. John A. Fair, Chief Strategy Officer (Age 50, Pay $453.61k)
• Mr. Mark Walters, VP of Operations (Age 67)
• Dr. David Friend, Chief Scientific Officer

Who are some of Daré Bioscience's key competitors?

Some companies that are related to Daré Bioscience include Centessa Pharmaceuticals (CNTA), DiaMedica Therapeutics (DMCAF), Praxis Precision Medicines (PRAX), Repare Therapeutics (RPTX), Inventiva (IVA), Arbutus Biopharma (ABUS), Esperion Therapeutics (ESPR), OrganiGram (OGI), Kinnate Biopharma (KNTE), Pardes Biosciences (PRDS), COMPASS Pathways (CMPS), Day One Biopharmaceuticals (DAWN), Gelesis (GLS), Khosla Ventures Acquisition (KVSA) and Heron Therapeutics (HRTX).
View all of DARE's competitors.

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

What is Daré Bioscience's stock symbol?

Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."

Who are Daré Bioscience's major shareholders?

Daré Bioscience's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.11%), BlackRock Inc. (0.72%), State Street Corp (0.21%), GSA Capital Partners LLP (0.15%), Renaissance Technologies LLC (0.12%) and Buckingham Strategic Partners (0.04%).
View institutional ownership trends for Daré Bioscience.

Which institutional investors are selling Daré Bioscience stock?

DARE stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP.
View insider buying and selling activity for Daré Bioscience or view top insider-selling stocks.

Which institutional investors are buying Daré Bioscience stock?

DARE stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Renaissance Technologies LLC, Citigroup Inc., Bank of New York Mellon Corp, Buckingham Strategic Partners, and State Street Corp.
View insider buying and selling activity for Daré Bioscience or or view top insider-buying stocks.

How do I buy shares of Daré Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Daré Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $1.16.

How much money does Daré Bioscience make?

Daré Bioscience has a market capitalization of $98.26 million. The biotechnology company earns $-38.70 million in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does Daré Bioscience have?

Daré Bioscience employs 16 workers across the globe.

What is Daré Bioscience's official website?

The official website for Daré Bioscience is www.darebioscience.com.

How can I contact Daré Bioscience?

Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at (858) 926-7655, via email at [email protected], or via fax at 617-494-1544.